Serum oncostatin M in multiple myeloma: Impact on disease severity and prognosis

European Journal of Haematology

Volumn 65, Issue 1, 2000, Pages 52-56

  Koskela, Kari ^a,b   Pelliniemi, T T ^a,b   Rajamaki A ^a,b   Pulkki, K ^a,b   Remes, K ^a,b  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

Cytokine; Multiple myeloma; Oncostatin M; Prognostic factor

Indexed keywords

ONCOSTATIN M;

ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE SEVERITY; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

ADULT; AGED; C-REACTIVE PROTEIN; FEMALE; FINLAND; HUMANS; INTERLEUKIN-6; LIFE TABLES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM PROTEINS; ONCOSTATIN M; OSTEOLYSIS; PEPTIDES; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0033935143     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2000.90167.x     Document Type: Article

References (39)

1. 1. ZHANG X, KLEIN B, BATAILLE R. Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood 1989;74:11-13.
2. 2. KLEIN B, ZHANG X, LU Z, BATAILLE R. Interleukin-6 in human multiple myeloma. Blood 1995;85:863-872.
3. 3. KISHIMOTO T, AKIRA S, NARAZAKI M, TAGA T. Interleukin-6 family of cytokines and gp130. Blood 1995;86:1243-1254.
4. 4. KLEIN B, BATAILLE R. Cytokine network in human multiple myeloma. Hematol Oncol Clin North Am 1992;6:273-284.
5. 5. NISHIMOTO N, OGATA A, SHIMA Y, et al. Oncostatin M, leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gp130. J Exp Med 1994;179:1343-1347.
6. 6. ZHANG X, GU Z, LU Z, et al. Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130. J Exp Med 1994; 177:1337-1342.
7. 7. HALLEK M, BERGSAGEL PL, ANDERSON KC. Multiple myeloma: Increasing evidence for a multistep transformation process. Blood 1998;91:3-21.
8. 8. KOSKELA K, PELLINIEMI T-T, REMES K, RAJAMÄKI A, PULKKI K. Serum oncostatin M in multiple myeloma: association with prognostic factors. Br J Haematol 1997;96:158-160.
9. 9. PELLINIEMI T-T, IRJALA K, MATTILA K, et al. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Blood 1995;85:765-771.
10. 10. LUDWIG H, NACHBAUR DM, FRITZ E, KRAINER M, HUBER H. Interleukin-6 is a prognostic factor in multiple myeloma. Blood 1991;77:2794-2795.
11. 11. BATAILLE R, BOCCADORO M, KLEIN B, DURIE BGM, PILERI A. C-reactive protein and β-2-microglobulin produce a simple and powerful myeloma staging system. Blood 1992;80:733-737.
12. 12. DURIE BGM, SALMON SE. A clinical staging system for multiple myeloma. Cancer 1975;36:842-854.
13. 13. ZARLING JM, SHOYAB M, MARQUARDT H, HANSON MB, LIOUBIN MN, TODARO GJ. Oncostatin M: a growth regulator produced by differentiated histiocytic lymphoma cell. Proc Natl Acad Sci USA 1986;83:9739-9743.
14. 14. MALIK N, KALLESTAD JC, GUNDERSON NL, et al. Molecular cloning, sequence analysis, and functional expression of a novel growth regulator, oncostatin M. Mol Cell Biol 1989; 9:2847-2853.
15. 15. ROSE TM, BRUCE G. Oncostatin M is a member of a cytokine family that includes leukemia-inhibitory factor, granulocyte colony-stimulating factor, and interleukin 6. Proc Natl Acad Sci USA 1991;88:8641-8645.
16. 16. JEFFERY E, PRICE V, GEARING DP. Close proximity of the genes for leukemia inhibitory factor and oncostatin M. Cytokine 1993;5:107-111.
17. 17. BROWN JT, LIOUBIN MN, MARQUARDT H. Purification and characterization of cytostatic lymphokines produced by activated human T lymphocytes. J Immunol 1987;139:2977-2983.
18. 18. GEARING DP, COMEAU MR, FRIEND DJ, et al. The IL-6 signal transducer, gp130: an oncostatin M receptor and affinity converter for the LIF receptor. Science 1992;255:1434-1437.
19. 19. MOSLEY B, DE IMUS C, FRIEND DJ, et al. Dual oncostatin M (OSM) receptors cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation. J Biol Chem 1996;271:32635-32643.
20. 20. LIU J, SPENCE MJ, WALLACE PM, FORCIER K, HELLSTRÖM I, VESTAL RE. Oncostatin M-spesific receptor mediates inhibition of breast cancer cell growth and down-regulation of the c-myc proto-oncogene. Cell Growth & Differ 1997;8:667-676.
21. 21. NAIR BC, DEVICO AL, NAKAMURA S, et al. Identification of a major growth factor for AIDS-Kaposi's sarcoma cells as oncostatin M. Science 1992;255:1430-1432.
22. 22. MILES SA, MARTINEZ-MAZA O, REZAI A, et al. Oncostatin M as potent mitogen for AIDS-Kaposi's sarcoma-derived cells. Science 1992;255:1432-1434.
23. 23. GROVE RI, EBERHARDT C, ABID S, et al. Oncostatin M is a mitogen for rabbit vascular smooth muscle cells. Proc Natl Acad Sci USA 1993;90:823-827.
24. 24. BRUCE GA, HOGGATT IH, ROSE TM. Oncostatin M is a differentiation factor for myeloid leukemia cells. J Immunol 1992;149:1271-1275.
25. 25. MODUR V, FELDHAUS MJ, WEYRICH AS, et al. Oncostatin M is a proinflammatory mediator. In vivo effects correlate with endothelial cell expression of inflammatory cytokines and adhesion molecules. J Clin Invest 1997;100:158-168.
26. 26. RICHARDS CD, BROWN JT, SHOYAB M, BAUMANN H, GAULDIE J. Recombinant Oncostatin M stimulates the production of acute phase proteins in HepG2 cells and rat primary hepalocytes in vitro. J Immunol 1992;148:1731-1736.
27. 27. GROVE RI, MAZZUCCO CE, RADKA SF, SHOYAB M, KIENER PA. Oncostatin M up-regulates low density lipoprotein receptors in HepG2 cells by a novel mechanism. J Biol Chem 1991; 266:18194-18199.
28. 28. WALLACE PM, MACMASTER JF, RILLEMA JR, PENG J, BURSTEIN SA, SHOYAB M. Thrombocytopoietic properties of oncostatin M. Blood 1995;86:1310-1315.
29. 29. HAMILTON JA, LEIZER T, PICCOLI DS, ROYSTON KM, BUTLER DM, CROATTO M. Oncostatin M stimulates urokinase-type plasminogen activator activity in human synovial fibroblasts. Biochem Biophys Res Commun 1991;180:652-659.
30. 30. LIU J, CLEGG CH, SHOYAB M. Regulation of EGR-1, c-jun and c-myc gene expression by oncostatin M. Cell Growth & Differ 1992;3:307-313.
31. 31. RAO MS, SYMES A, MALIK N, SHOYAB M, FINK GS, LANDIS SC. Oncostatin M regulates VIP expression in a human neuroblastoma cell line. Neuro Rep 1992;3:865-868.
32. 32. TANI Y, NISHIMOTO N, OGATA A, SHIMA Y, YOSHIZAKI K, KISHIMOTO T. gp130 in human myeloma/plasmacytoma. Curr Top Microbiol Immunol 1995;194:229-233.
33. 33. GU Z, COSTES V, LU Z, et al. InterIeukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop. Blood 1996;88:3972-3986.
34. 34. WESTENDORF JJ, JELINEK DF. Growth regulatory pathways in myeloma. Evidence for autocrine oncostatin M expression. J Immunol 1996;157:3081-3088.
35. 35. BROWN JT, ROWE JM, LIU J, SHOYAB M. Regulation of IL-6 expression by oncostatin M. J Immunol 1991;147:2175-2180.
36. 36. BARILLÉ S, AKHOUNDI C, COLLETTE M, et al. Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells. Blood 1997;90: 1649-1655.
37. 37. TAMURA T, UDAGAWA N, TAKAHASHI N, et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin-6. Proc Natl Acad Sci USA 1993;90:11924-11928.
38. 38. BATAILLE R, CHAPPARD D, KLEIN B. Mechanisms of bone lesions in multiple myeloma. Hematol Oncol Clin North Am 1992;6:285-295.
39. 39. WIERZBOWSKA A, URBANSKA-RYS H, ROBAK T. Circulating IL-6-type cylokines and sIL-6R in patients with multiple myeloma. Br J Haematol 1999;105:412-419.